Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination  by Lee, Alvin & Chia, Sing Joo
Asian Journal of Urology (2015) 2, 187e193HOSTED BY Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/ajurASIAN FOCUSContemporary outcomes in the detection
of prostate cancer using transrectal
ultrasound-guided 12-core biopsy in
Singaporean men with elevated prostate
specific antigen and/or abnormal digital
rectal examination
Alvin Lee a, Sing Joo Chia b,*a Yong Loo Lin School of Medicine, National University of Singapore, Singapore
b Department of Urology, Tan Tock Seng Hospital, SingaporeReceived 17 May 2015; received in revised form 29 July 2015; accepted 12 August 2015
Available online 3 September 2015KEYWORDS
Digital rectal
examination;
Oncology;
Prostate cancer;
Prostate specific
antigen;
Transrectal-
ultrasound;
Biopsy* Corresponding author.
E-mail address: sing_joo_chia@ttsh
Peer review under responsibility o
http://dx.doi.org/10.1016/j.ajur.2015
2214-3882/ª 2015 Editorial Office of A
article under the CC BY-NC-ND licenseAbstract Objective: Despite being the third commonest cancer in Singaporean men, there is
a dearth of basic data on the detection rate of prostate cancer and post-procedure complica-
tion rates locally using systematic 12-core biopsy. Our objective is to evaluate prostate cancer
detection rates using 12-core prostate biopsy based on serum prostate specific antigen (PSA)
levels and digital rectal examination (DRE) findings in Singaporean men presenting to a
single tertiary centre. The secondary objective is to evaluate the complication rates of
transrectal prostate biopsies.
Methods: We retrospectively examined 804 men who underwent first transrectal-ultrasound
(TRUS) guided 12-core prostate biopsies from January 2012 to April 2014. Prostate biopsies
were performed on men presenting to a tertiary institution when their PSA levels were
4.0 ng/mL and/or when they had suspicious DRE findings.
Results: Overall prostate cancer detection rate was 35.1%. Regardless of DRE findings, patients
were divided into four subgroups based on their serum PSA levels: 0e3.99 ng/mL, 4.00
e9.99 ng/mL, 10.00e19.99 ng/mL and 20.00 ng/mL and their detection rates were 9.5%,
20.9%, 38.4% and 72.3%, respectively. The detection rate of cancer based on suspicious DRE
findings alone was 59.2% compared to 36.5% based on serum PSA cut-off of 4.0 ng/mL alone.
The post-biopsy admission rate for sepsis was 1.5%..com.sg (S.J. Chia).
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188 A. Lee, S.J. ChiaConclusion: In conclusion, using contemporary 12-core biopsy methods, the local prostate can-
cer detection rate based on serum PSA and DRE findings has increased over the past decade
presumably due to multiple genetic and environmental factors. Post-biopsy sepsis remains
an important complication worldwide.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
According to the Singapore Cancer Registry, prostate can-
cer was the third commonest cancer in men during
2009e2013, making up 12.1% of all cancers reported locally
[1]. The incidence of prostate cancer has been rapidly
increasing in the last decade. Potential reasons for this
increase include the advent of better detection methods,
an aging population as well as a shift in dietary patterns [2].
However, the incidence of prostate cancer in Singapore is
still much lower compared to other Western countries such
as the USA [3]. In years to come, prostate cancer will likely
become an increasingly important health issue as its diag-
nosis and management continues to evolve. Hence, it is
essential to review and update our current diagnostic
pathway based on the latest evidence so as to further
improve patient outcomes.
Current established detection methods of prostate
cancer include digital rectal examination (DRE), serum
prostate specific antigen (PSA) and transrectal ultrasound
(TRUS)-guided prostate biopsy using a systematic 12-core
method. Serum PSA cut-offs of between 2.5 and 4.0 ng/mL
have been used by studies on prostate cancer screening
such as the European Randomized Study of Screening
of Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal
and Ovarian cancer screening trial (PLCO) [4,5].
The median PSA in Singaporeans is lower than that re-
ported in Caucasian men [6]. However, there is a dearth of
basic data for the detection rate of prostate cancer ac-
cording to serum PSA levels and DRE findings. In this
retrospective study, we endeavored to examine the
detection rate of prostate cancer on contemporary 12-core
TRUS-biopsy in men with either PSA 4.0 ng/mL and/or
have suspicious DRE findings and also to analyze the
complication rates of biopsy.
2. Materials and methods
In our study, we retrospectively analyzed 804 men who
underwent TRUS-guided prostate biopsy in a single institu-
tion from January 2012 to April 2014. The indications for
prostate biopsy were serum PSA 4.00 ng/mL and/or DRE
findings suspicious for malignancy (including induration,
irregularity, nodularity and asymmetry). Subjects who had
previous prostate biopsy, prostate surgery, known diagnosis
of prostate cancer and previous use of 5-a reductase in-
hibitors were excluded from the study. All subjects had
at least one or more serum PSA levels measured and
were subjected to DRE. All PSA measurements were
performed using PSA Hybritech Assay and only the latestresults taken prior to prostate biopsy were used in our
analysis.
For the prostate biopsy, patients were placed in the
left lateral position and a TRUS-guided needle biopsy
of the prostate was performed. The ultrasound
scanner used was Siemens ACUSON X150. The prostate
volume was measured using the ellipsoid formula (p/
6  craniocaudal  transverse  anteroposterior length).
Patients underwent systematic 12-core or 18-core biopsy
depending on the performing clinician’s evaluation of the
prostate volume and DRE findings. Additional cores were
taken at the urologist’s discretion such as taking a core
from a hypoechoic lesion seen on ultrasound. The core
specimens were examined by pathologists in the same
institution. Prostate cancers with Gleason sum 7 were
considered clinically significant. For peri-procedure sepsis
prophylaxis, men were given 7 days of peri-procedural oral
ciprofloxacin tablets (3 days pre- and 4 days post-
procedure) and one dose of intra-muscular gentamicin
120 mg just before the procedure. Bisacodyl suppositories
were given for rectal preparation on the day of the pro-
cedure. The rectum was cleansed using povidone-iodine
solution just before needle biopsy.
We further evaluated the post-procedural complications
which required inpatient admission such as infection. In
men who developed post-procedure fever, they were given
intravenous cefepime and a single dose of amikacin as per
institution protocol. The antibiotic used would then be
rationalised based on culture and sensitivities.
Statistical analysis was performed using IBM SPSS Sta-
tistics 20.0. t-test, KruskaleWallis and Pearson Chi-square
tests were used to evaluate any differences in continuous
and categorical variables respectively. Ethics approval was
obtained from the Domain-Specific Review Board (DSRB)
before commencement of data collection (2010/00318).
3. Results
Eight hundred and four men underwent first TRUS-guided
prostate biopsy. Seven hundred and thirty-three (91.2%)
were Chinese while 71 (8.8%) were from other races such as
Malay, Indian and Caucasian. Their mean age was 68.2  8.9
years, median prostate volume was 45.0 mL and median
serum PSA levels were 8.6 ng/mL (Table 1). The systematic
12-core prostate biopsy were performed on 468/522 (89.7%)
of men without cancer compared to 236/282 (83.7%) men
with cancer (p < 0.01).
Two hundred and eighty-two men (35.1%) had a positive
biopsy result for prostate cancer, which included 215 men
(76.2%) who had clinically significant disease (Gleason
Table 1 Patient characteristics.
Demographics Total Men without cancer Men with cancer p-Value
Patients, n (%) 804 (100.0) 522 (64.9) 282 (35.1)
Age (year, mean  SD) 68.2  8.9 66.8  8.6 70.7  8.7 <0.001a
No. of cores, median (IQR) 12.0 (12.0, 12.0) 12.0 (12.0, 12.0) 12.0 (12.0, 12.0) <0.001b
DRE findings
Normal, n (%) 566 (100.0) 425 (75.1) 141 (24.9)
Suspicious, n (%) 238 (100.0) 97 (40.8) 141 (59.2) <0.001c
PV (mL, median (IQR)) 45.0 (30.0, 64.9) 48.2 (33.7, 68.0) 39.0 (28.0, 57.5) <0.001b
Serum PSA (ng/mL, median (IQR)) 8.6 (6.0, 16.4) 7.2 (5.4, 10.5) 16.0 (8.0, 82.8) <0.001b
PSA density (ng/mL2, median (IQR)) 0.196 (0.120, 0.382) 0.152 (0.107, 0.237) 0.463 (0.205, 1.845) <0.001b
IQR, inter quartile range; PV, prostate volume; PSA, prostate specific antigen.
a t-test.
b KruskaleWallis test.
c Chi-square test.
Prostate cancer detection in Singapore 189sum 7). Men with prostate cancer were older (70.7 vs.
66.8 years, p < 0.001) and had higher PSA levels (16.0 vs.
7.2 ng/mL, p < 0.001) despite having smaller prostates
(39.0 vs. 48.2 mL, p < 0.001). They were also more likely to
have suspicious DRE findings (59.2% vs. 40.8%, p < 0.001)
(Table 1). Among the 522 men without cancer, 82 (15.7%)
men underwent a second repeat biopsy, of which 14 (17.1%)
men had a positive result for cancer. Four patients under-
went a third biopsy of which one (25%) of them had a
positive biopsy.
Out of the 762/804 (94.8%) men with serum
PSA  4.00 ng/mL, 278/762 (36.5%) had a positive biopsy.
Serum PSA levels were categorised into four main cate-
gories: 0e3.99 ng/mL, 4.00e9.99 ng/mL, 10.00e19.99 ng/
mL and 20.00 ng/mL. Their corresponding overall prostate
cancer detection rates, regardless of DRE findings, were
4/42 (9.5%), 87/417 (20.9%), 66/172 (38.4%) and 125/173
(72.3%), respectively (Table 2).
In total, 238/804 (29.6%) men had suspicious DRE find-
ings. The detection rate of cancer based on DRE alone is
141/238 (59.2%). When a cut-off of PSA 4.00 ng/mL was
used, the detection rate of cancer in patients with suspi-
cious DRE was increased to 137/196 (69.9%). The corre-
sponding overall cancer detection rates of suspicious DRE
findings were 4/42 (9.5%), 21/54 (38.9%), 20/34 (58.8%) and
96/108 (88.9%) when serum PSA levels were 0e3.99 ng/mL,Table 2 Overall prostate cancer detection rates based on seru
PSA
(ng/mL)
Patients
(n)
Cancer detection
rate, n (%)
Normal DRE
Incidence (n) Canc
0e3.99 42 4 (9.5) e e
4.00e9.99 417 87 (20.9) 363 66
10.00e19.99 172 66 (38.4) 138 46
20.00 173 125 (72.3) 65 29
Total 804 282 (35.1) 566 141
4.00e19.99 589 153 (26.0) 501 112
4.00 762 278 (36.5) 566 141
<20.00 631 157 (24.9) 501 112
*p < 0.05, Chi-square test.
DRE, digital rectal examination; PSA, prostate specific antigen.4.00e9.99 ng/mL, 10.00e19.99 ng/mL and 20.00 ng/mL,
respectively (Table 2). The corresponding clinically signifi-
cant cancer detection rates based on suspicious DRE find-
ings were 2/42 (4.8%), 16/54 (29.6%), 17/34 (50.0%) and 95/
108 (88.0%), respectively (Table 3). Men with prostate
cancer were more likely to have suspicious DRE findings in
the 4.00e9.99 ng/mL, 10.00e19.99 ng/mL and 20.00 ng/
mL serum PSA categories (p Z 0.001, p Z 0.01 and
p < 0.001, respectively). Table 4 summarises the sensi-
tivity, specificity, positive predictive value and negative
predictive value of DRE.
Among the 762 men with PSA 4.00 ng/mL, 161 (21.1%)
had benign prostate hyperplasia while 252 (33.1%) had
prostatitis on biopsy. Forty-one (5.4%) had atypical glands
while 29 (3.8%) had high grade prostatic intra-epithelial
neoplasia on biopsy. One (0.1%) patient had a spindle cell
neoplasm. Among the 41 men with atypical glands on bi-
opsy, 23 underwent a second repeat biopsy, of which nine
(39.1%) had a positive biopsy for prostate cancer.
Twelve (1.5%) men were admitted for inpatient hospital
stay due to post-procedure sepsis, of which three (25.0%)
developed severe sepsis. One suffered from cardiorespira-
tory collapse (pulseless electrical activity) and died.
Another patient was sent to the surgical intensive care unit
for septic encephalopathy and the last patient had hypo-
tension which was fluid responsive. Seven (58.3%) had am PSA levels and DRE findings.
Abnormal DRE
er detection, n (%) Incidence (n) Cancer detection, n (%)
42 4 (9.5)
(18.2)* 54 21 (38.9)*
(33.3)* 34 20 (58.8)*
(44.6)* 108 96 (88.9)*
(24.9)* 238 141 (59.2)*
(22.4)* 88 41 (46.6)*
(24.9)* 196 137 (69.9)*
(22.4)* 130 45 (34.6)*
Table 3 Clinically-significant prostate cancer detection rates based on serum PSA levels and DRE findings.
PSA (ng/mL) Patients (n) High-grade cancer
detection rate, n (%)
Normal DRE Abnormal DRE
Incidence (n) High-grade cancer
detection, n (%)
Incidence (n) High-grade cancer
detection, n (%)
0e3.99 42 2 (4.8) e e 42 2 (4.8)
4.00e9.99 417 45 (10.8) 363 29 (8.0)* 54 16 (29.6)*
10.00e19.99 172 48 (27.9) 138 31 (22.5)* 34 17 (50.0)*
20.00 173 120 (69.4) 65 25 (38.5)* 108 95 (88.0)*
Total 804 215 (26.7) 566 85 (15.0)* 238 130 (54.6)*
4.00e19.99 589 93 (15.8) 501 60 (12.0)* 88 33 (37.5)*
4.00 762 213 (28.0) 566 85 (15.0)* 196 128 (65.3)*
<20.00 631 95 (15.1) 501 60 (12.0)* 130 35 (26.9)*
*p < 0.05, Chi-square test.
DRE, digital rectal examination; PSA, prostate specific antigen.
190 A. Lee, S.J. Chiapositive blood culture which grew Escherichia coli, of
which only one of them was positive for extended-spectrum
b-lactamase.
4. Discussion
According to the Singapore Cancer Registry, 3456 new cases
of prostate cancer were diagnosed during 2009e2013. The
age-standardised incidence rate for prostate cancer has
risen dramatically over the last 40 years from 5.2/100,000
in 1973e1977 to 28.1/100,000 in 2009e2013. Prostate
cancer also has the 5th highest cancer mortality in
Singapore. The 5-year age-specific standardised observed
survival of prostate cancer was 74.86% from 2009 to 2013
compared to 70.77% from 2004 to 2008 [1]. This is in com-
parison with an observed survival of 98.9% in the USA
from 2004 to 2010 [3] and 81.4% in England from 2005 to
2009 [7].
In this study, we retrospectively analyzed the detection
rate of prostate cancer in patients undergoing biopsy from
January 2012 to April 2014 in a single tertiary hospital. With
increasing use of serum PSA testing in the urology outpa-
tient setting as well as part of individual health-screening
packages offered in primary care, there is a need toTable 4 Characteristics of DRE at various PSA categories
for overall prostate cancer detection on biopsy.
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
DRE þ
PSA < 4.00 ng/mL e e 9.5 e
DRE þ
PSA 4.00e9.99 ng/mL 24.1 90.0 38.9 81.8
DRE þ
PSA 10.00e19.99 ng/mL 30.3 86.8 58.8 66.7
DRE þ
PSA  20.00 ng/mL 76.8 75.0 88.9 55.4
DREþ
any PSA 50.0 81.4 59.2 75.1
DRE, digital rectal examination; PSA, prostate specific antigen;
PPV, positive predictive value; NPV, negative predictive value.examine the prostate cancer detection rates based on
serum PSA levels and DRE findings using contemporary 12-
core prostate biopsy as well as its complication rates. This
will help guide urologists and patients in making well-
informed decisions regarding the indications for biopsy,
together with the discussion of the potential risks.
For the past 8 years, there has been no update on the
detection rate of prostate cancer using 12-core TRUS biopsy
in our local population. Our study provides some insight into
the diagnostic yield of serum PSA and DRE using contem-
porary biopsy methods. Our results demonstrated a higher
detection rate of prostate cancer compared to previous
studies done locally. In men with serum PSA less than
20.00 ng/mL, the detection rate of prostate cancer in our
current study is 24.9%, compared to previous data of 19.4%
reported by Ng et al. (2002) [8] and 8.9% reported by Tan
et al. (1995) [9]. Sextant core biopsy and 10-core biopsy
were performed in the study by Tan et al. [9] and Ng et al.
[8] respectively, compared to systematic 12-core biopsy in
our current study. The indications for prostate biopsy in all
three studies were similar. Due to differences in the sample
populations, one can only postulate that the current
increased detection rate is due to an increase in the num-
ber of cores taken on TRUS prostate biopsy, improvement in
technique of biopsy as well as increasing incidence of
prostate cancer which is likely multifactorial [10].
In patients with serum PSA level of 4.00e9.99 ng/mL,
the detection rate of overall prostate cancer, regardless of
DRE findings, was 20.9%. This rate is less than the 26.1%
detection rate reported by Catalona et al. [11] in American
men using only sextant biopsy. Meanwhile, Andriole et al.
[4] reported a detection rate of 35.7% (297/832) from the
initial screening round of PLCO. Within the same PSA range
of 4.00e9.99 ng/mL, Egawa et al. [12] reported a detection
rate of 15.8% in Japanese men who underwent a sextant
biopsy while Masumoto et al. [13] reported a rate of 19.7%
in men who underwent systematic 12-core biopsy. Similarly,
Seo et al. [14] reported a 19.6% detection rate in a Korean
study population of which only about 50% were subjected to
a 12-core biopsy. Various factors may explain the differ-
ences in prostate cancer detection rate across various
geographical populations. These include differences in
sample characteristics (e.g., screened vs. unscreened),
Prostate cancer detection in Singapore 191biopsy indications and methods, the number of cores taken
during biopsy and inherent ethnic differences [10]. In
particular, many Asian countries such as Singapore may
be losing their protective cultural factors and acquiring
high-risk lifestyle, dietary or environmental factors which
may account for the decreasing gap in prostate cancer
incidence and detection rates amongst Asian and Western
populations [2].
DRE remains a relevant and important tool for clini-
cians in the detection of prostate cancer [15e17]. In our
study, the sensitivity and specificity of DRE for prostate
cancer detection, regardless of PSA levels, are 50.0% and
81.4% respectively. The detection rate of prostate cancer
based on suspicious DRE findings alone (59.2%) is superior
than that of using serum PSA levels (at a cut-off of
4.00 ng/mL Z 36.5%) alone, with a combined detection
rate of 69.9% (if both PSA 4.00 ng/mL and suspicious
DRE). It has to be noted that DRE is not a sensitive test for
prostate cancer in patients with intermediate PSA levels
(4.00e9.99 ng/mL) with suspicious DRE findings being only
able to detect 24.1% of prostate cancers on initial biopsy.
However, DRE is still useful in picking up cancers which
are likely to be clinically significant. 92.2% of cancer pa-
tients who had suspicious DRE findings had a Gleason sum
of 7 and above (analysis not shown) on histopathological
analysis. This is concordant with other studies that
demonstrated that an abnormal DRE was an independent
predictor of cancer, especially clinically significant can-
cers [18e20].
It is noted that in men with PSA levels between 0 and
3.99 ng/mL, DRE had a low positive predictive value of
prostate cancer e about 11 biopsies would be required
to diagnose one cancer (9.5% detection rate) and 21 bi-
opsies for one significant cancer (4.8% detection rate).
All four men diagnosed with cancer had serum PSA
<2.50 ng/mL. There is currently no good evidence to
demonstrate any reduction in morbidity and mortality
from prostate cancer when it was detected by DRE.
Bozeman et al. [21], Carvalhal et al. [22], Fowler et al.
[23] and Schro¨der et al. [24] have all previously reported
that the positive predictive value of DRE in men with PSA
levels of 0e3.99 ng/mL is general low (10%, 8.8%, 13% and
19%, respectively). In another study in Korea where there
is a relatively lower incidence of prostate cancer, Shim
et al. [25] found that there were no differences in
detection rates of cancer based on DRE findings (abnormal
vs. normal) in men 45e59 years as well as men with PSA
levels 2.50e3.99 ng/mL. Gosselaar et al. [26] studied men
with PSA 2.00e3.99 ng/mL and found that PSA as a biopsy
indication outperformed DRE in cancer detection at the
cost of overdiagnosis of clinically insignificant cancers
and was also able to pick up potentially aggressive tu-
mours that were T1c cancers. Vis et al. [27] suggested that
DRE as a screening test for prostate cancer at low PSA
values may be replaced by screening using PSA testing
alone as 289 DREs are required to find one case of clini-
cally significant disease and 96 DREs to diagnose any
prostate cancer. Unfortunately, our study lacks data on
the cancer detection rate in men with PSA 0e3.99 ng/mL
and normal DRE for comparison. With only a small number
of men with PSA 0e3.99 ng/mL in our study, caution
should be taken in making any firm conclusions regardingthe relevance of DRE in men with low PSA levels in our
local population.
Infection-related complications remain the greatest
concern in patients undergoing prostate biopsy via the
transrectal route, especially with the emergence of anti-
biotic resistant strains [28e31]. Only 1.5% (12/804) of men
who underwent TRUS biopsy in our institution suffered
infection-related complications which required inpatient
admission. Unfortunately, one patient (0.1%) suffered a
mortality due to cardio-respiratory collapse from sepsis.
The patient who had tested positive for extended spec-
trum b-lactamase was treated with ertapenem with no
serious sequalae. The incidence of infectious complica-
tions requiring hospitalization following prostate biopsy
via transrectal route ranges from 0.6% to 4.1% [32]. Hence,
the post-TRUS biopsy infection rates in our institution are
similar to other centres around the world and more
importantly, our data can be used in the counselling of
men for prostate biopsy locally.
There are currently no official guidelines regarding
prostate cancer screening in Singapore. PSA tests are usu-
ally offered as part of public health screening packages via
general practitioners. In the urology clinic, PSA testing is
often part of the work-up in male patients presenting with
lower urinary tract symptoms. Both the American Urologi-
cal Association (AUA) and European Association of Urology
(EAU) conclude that mass screening for prostate cancer
is likely to be inappropriate and that early detection is
a shared decision to be made by a well-informed man
[33,34]. Both do not suggest routine PSA testing in men
older than 70e75 years as the benefit of reducing prostate
cancer specific mortality may not be actualized. Much ev-
idence which form the basis of these guidelines was ob-
tained from Western populations and its generalisability to
Asian populations has yet to be proven and will unlikely be
available in the near future due to the lack of well-designed
trials in the region. While PSA >4.0 ng/mL serves as a
traditional cut-off to offer a prostate biopsy, it has to be
emphasised that PSA levels reflect a continuum of risk and
even men with PSA <4.0 ng/mL may harbour clinically
significant cancer. Perhaps, more could be done to help
improve the risk stratification process with regard to pros-
tate cancer via more complex, multi-variable prediction
models/nomograms, rather than using blunt PSA cut-offs.
In recent years, advancements in magnetic resonance
imaging (MRI) have made it an emerging tool in the arena of
prostate cancer detection [35e37]. The use of multi-
parametric MRI followed by selective use of MR-guided bi-
opsy have been shown to reduce the detection of low-risk,
likely clinically insignificant cancers as well as the need for
biopsy [37]. More importantly, they help improve detection
of high-risk disease [37]. However, these modalities lack
sufficient established evidence of long-term oncological
outcomes to be accepted as standard practice. Locally, the
use of mpMRI and targeted biopsies have largely been based
on shared decisions between clinicians and patients as well
as the availability of the required resources and consider-
ation of financial costs.
Admittedly, there are some limitations which have to be
considered before drawing any firm conclusions from our
analysis. Firstly, our study cohort was recruited from an
unscreened population who were referred to the urology
192 A. Lee, S.J. Chiaclinic for raised PSA, suspicious DRE findings or urinary
symptoms. Hence selection bias cannot be excluded.
Regrettably, there was no data on the indications of indi-
vidual PSA testing. Several studies have reported increased
risk of prostate cancer detection in men with elevated PSA
levels and no or mild lower urinary tract symptoms [38,39],
and hence the lack of such information exposed our study
to possible detection bias. DREs were performed by multi-
ple urologists and urological trainees in a tertiary hospital,
inevitably resulting in inter-observer variability. We
reduced this variability by having a standardised protocol
for our ultrasound and biopsy method. Many studies have
attempted to investigate ways to improve the diagnostic
ability of serum PSA such as by adjusting for age, prostate
volume and body mass index [40e42] and we will be looking
into the application of such adjustments and/or nomograms
in our local population.
In our current retrospective study, we endeavored to
evaluate the detection rates of prostate cancer using serum
PSA levels and DRE findings. Our analysis revealed that
prostate cancer detection rate based on serum PSA and DRE
findings has increased over the last decade. In men with
serum PSA level of 4.00e9.99 ng/mL, the detection rate of
prostate cancer, regardless of DRE findings, is 20.9%. This
rate suggests that local prostate cancer detection rates are
lower than that reported in studies involving Caucasian
populations, likely reflecting ethnical differences. Post-
procedural sepsis remains a pertinent challenge to men
undergoing prostate biopsy worldwide.
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